Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sulkowski

Showing results (261-270 of 408) with videos related to

Pageof 41
Sort By:
AIDS Patient Care and Stds|May 10, 2016
Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIVUsama Bilal, Bryan Lau, Mariana Lazo, et al.
Open Forum Infectious Diseases|May 9, 2017
Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon EraTanyaporn Wansom, Oluwaseun Falade-Nwulia, Catherine G Sutcliffe, et al.
The Journal of Clinical Investigation|July 7, 2022
Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatmentTanner Grudda, Hyon S Hwang, Maraake Taddese, et al.
Hepatology (Baltimore, Md.)|October 31, 2002
Treatment of chronic hepatitis C: a systematic reviewGeetanjali Chander, Mark S Sulkowski, Mollie W Jenckes, et al.
Hepatology (Baltimore, Md.)|December 25, 2004
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfectionShruti H Mehta, David L Thomas, Michael Torbenson, et al.
The Journal of Infectious Diseases|December 10, 2024
Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune ActivationJaiprasath Sachithanandham, Julia Leep-Lazar, Jeffrey Quinn, et al.
BMC Infectious Diseases|December 17, 2009
Hepatic profile analyses of tipranavir in Phase II and III clinical trialsJaromir Mikl, Mark S Sulkowski, Yves Benhamou, et al.
Roczniki Akademii Medycznej W Bialymstoku (1995)|January 1, 1997
Effects of pentoxifylline on some peripheral blood parameters and haemostasis in acute pulmonary tissue injury after cyclophosphamideM Sulkowska, B Musiatowicz, S Sulkowski, et al.
Nature Reviews. Gastroenterology & Hepatology|March 10, 2011
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis CMark S Sulkowski, Curtis Cooper, Bela Hunyady, et al.
Journal of Viral Hepatitis|March 27, 2026
Utilizing Telemedicine to Engage Rural Patients With Substance Use Disorders in Low Barrier Hepatitis C TreatmentKristi C Hill, Sherilyn Brinkley, Maria Latimer, et al.
Pageof 41

Showing results (261-270 of 408) with videos related to

Sort By:
Pageof 41
AIDS Patient Care and Stds|May 10, 2016
Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIVUsama Bilal, Bryan Lau, Mariana Lazo, et al.
Open Forum Infectious Diseases|May 9, 2017
Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon EraTanyaporn Wansom, Oluwaseun Falade-Nwulia, Catherine G Sutcliffe, et al.
The Journal of Clinical Investigation|July 7, 2022
Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatmentTanner Grudda, Hyon S Hwang, Maraake Taddese, et al.
Hepatology (Baltimore, Md.)|October 31, 2002
Treatment of chronic hepatitis C: a systematic reviewGeetanjali Chander, Mark S Sulkowski, Mollie W Jenckes, et al.
Hepatology (Baltimore, Md.)|December 25, 2004
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfectionShruti H Mehta, David L Thomas, Michael Torbenson, et al.
The Journal of Infectious Diseases|December 10, 2024
Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune ActivationJaiprasath Sachithanandham, Julia Leep-Lazar, Jeffrey Quinn, et al.
BMC Infectious Diseases|December 17, 2009
Hepatic profile analyses of tipranavir in Phase II and III clinical trialsJaromir Mikl, Mark S Sulkowski, Yves Benhamou, et al.
Roczniki Akademii Medycznej W Bialymstoku (1995)|January 1, 1997
Effects of pentoxifylline on some peripheral blood parameters and haemostasis in acute pulmonary tissue injury after cyclophosphamideM Sulkowska, B Musiatowicz, S Sulkowski, et al.
Nature Reviews. Gastroenterology & Hepatology|March 10, 2011
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis CMark S Sulkowski, Curtis Cooper, Bela Hunyady, et al.
Journal of Viral Hepatitis|March 27, 2026
Utilizing Telemedicine to Engage Rural Patients With Substance Use Disorders in Low Barrier Hepatitis C TreatmentKristi C Hill, Sherilyn Brinkley, Maria Latimer, et al.
Pageof 41